UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.05 +0.05 (+0.06%) GOLD FUTURES
2,312.70 +1.70 (+0.07%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
46,973.48 +1,169.09 (+2.55%)
Quest Diagnostics Incorporated (DGX)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 137.55 |
| Open | 137.42 |
| Bid | 135.81 x 800 |
| Ask | 135.86 x 1100 |
| Day's range | 135.35 - 137.42 |
| 52-week range | 119.59 - 145.58 |
| Volume | |
| Avg. volume | 1,035,668 |
| Market cap | 15.146B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 18.35 |
| EPS (TTM) | 7.43 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 3.00 (2.18%) |
| Ex-dividend date | 05 Apr 2024 |
| 1y target est | 147.00 |
ZacksReasons to Retain Quest Diagnostics (DGX) Stock for Now
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
ZacksQuest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
PR NewswireQuest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.
© 2024 Yahoo. All rights reserved.